Uncoupling between Ig somatic hypermutation and oncogene mutation in mouse lymphoma  by Vincent, Christelle et al.
Biochimica et Biophysica Acta 1793 (2009) 418–426
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbamcrUncoupling between Ig somatic hypermutation and oncogene mutation in
mouse lymphoma
Christelle Vincent 1, Véronique Trufﬁnet 1, Remi Fiancette, Barbara Petit, Nadine Cogné,
Michel Cogné, Yves Denizot ⁎
UMR CNRS 6101, Centre National de la Recherche Scientiﬁque, Université de Limoges, FranceAbbreviations: BL, Burkitt lymphoma; LCR, locus con
lin; CSR, class switch recombination; ES, embryonic st
activation-induced cytidine deaminase
⁎ Corresponding author. UMR CNRS 6101, Faculté M
87025, Limoges, France.
E-mail address: yves.denizot@unilim.fr (Y. Denizot).
1 CV and VT contributed equally to this work.
0167-4889/$ – see front matter © 2008 Elsevier B.V. Al
doi:10.1016/j.bbamcr.2008.10.011a b s t r a c ta r t i c l e i n f oArticle history: Burkitt lymphoma (BL) featu
Received 21 August 2008
Received in revised form 21 October 2008
Accepted 21 October 2008
Available online 3 November 2008
Keywords:
B cell
Cell activation
Gene regulationres translocations linking c-myc to the immunoglobulin heavy chain (IgH) locus.
By inserting a c-myc gene under the control of the 3′IgH locus control region (LCR) into the mouse genome,
we generated c-myc–3′LCR mice that develop clonal BL or diffuse anaplastic lymphoma. We show in the
present study that while BL from c-myc–3′LCR mice would be classiﬁed as pre-germinal center (GC) cells due
to the absence of both BCL-6 expression and somatic hypermutation (SHM) in VH sequences, they show a
high level of SHM focused on the c-myc oncogene itself. This observation suggests that the c-myc–3′IgH LCR
tandem association drives development of lymphoma from naïve B cells by speciﬁcally recruiting AID activity
on c-myc in a process that early becomes independent from antigen selection and where the successive
rounds of SHM rather rely on the selection of the most efﬁcient mutations for oncogene deregulation. Similar
to the translocated c-myc gene in human BL, mutations were found in ﬁrst exon and 5′ ﬂanking sequences of
transgenic c-myc and specially focused on negative regulatory elements, thus leading to high and constitutive
oncogene expression. In conclusion while 3′IgH transcriptional enhancers in c-myc–3′LCR mice ﬁrst simply
act in cis to slightly stimulate c-myc transcription in untransformed B cells, the occurrence of lymphoma
appears to result from an additional mechanism necessitating AID-driven mutations within the ﬁrst exon and
5′ ﬂanking sequences which does not occur in parallel but rather circumvents antigen-driven selection.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Normal expression of c-myc is tightly linked to the early G1 phase
of the cell cycle and plays a critical role in cell proliferation,
differentiation, metabolism and apoptosis [1]. Burkitt lymphoma
(BL) is characterized by speciﬁc chromosomal translocations involving
the c-myc gene and one of the immunoglobulin loci (Igκ, Igλ and IgH)
[2]. The translocated c-myc then loses its normal control and is
constitutively expressed throughout the cell cycle in B lineage cells,
the oncogene deregulation being considered the result from juxtapo-
sition to the immunoglobulin gene enhancers. In 80% of cases, the
translocation involves the IgH locus [2], itself regulated by a complex
interplay of 5′ (Eμ) and 3′ regulatory elements (hs3a, hs1,2, hs3b and
hs4) responsible for tissue- and stage-speciﬁc regulation of both
transcription and rearrangements [3]. Like BL, mouse plasmacytomastrol region; Ig, immunoglobu-
em; GC, germinal center; AID,
édecine, 2 rue Dr. Marcland,
l rights reserved.exhibit chromosomal translocations that juxtapose c-myc to Ig [4]. In
addition, it was found that the translocated c-myc allele in BL cell lines
had incorporated multiple mutations largely focused within the ﬁrst
non-translated exon of c-myc [5]. It was suggested that translocation
of c-myc into the IgH locus could have transformed c-myc into
becoming a substrate for the antibody somatic hypermutation
mechanism (SHM) [6], thus suggesting that human BL arise from
somatically mutated, post-germinal center (post-GC) B cells [7]. In
such a view and even if a single oncogene is involved, malignant
transformation needs several “hits”, the ﬁrst being increased
transcription, then followed with hypermutation. It is indeed
noteworthy that translocation of oncogenes in the vicinity of Ig
enhancers is not sufﬁcient by itself for the induction of lymphoma and
can be readily detected in B cells from normal individuals [8,9].
Recently, we reported that the complete 3′ IgH locus control region
(LCR) (i.e. encompassing hs3a, hs1,2, hs3b and hs4 elements) in its
palindromic conﬁguration and independently of any other cis-acting
element might be sufﬁcient to deregulate c-myc in a transgenic mouse
model [10]. The transgenic c-myc included the noncoding ﬁrst exon
with P1/P2 promoters. Interestingly, c-myc–3′LCR transgenic mice
developed lymphomaswithin fewweeks. BL proliferations occurred in
75% of cases while the remaining 25% were characterized as diffuse
anaplastic lymphomas. The observed spectrum of tumors provides
Fig. 1. Generation of c-myc–3′LCR transgenic mice. Schematic diagrams of the murine c-
myc locus and of the c-myc–3′LCR transgene. The transgene consisted in a cassette
carrying themouse c-myc genomic fragment containing the three c-myc exons and its 5′
untranslated regulatory region encompassing P1 and P2 promoters. c-myc gene was
under the control of the four 3′ IgH enhancers (hs3a; hs1,2; hs3b; hs4) assembled
according to their endogenous palindromic conﬁguration. The cassette was ﬂanked by
the chicken β-globin HS4 insulator. Arrows indicated the position of backward and
forward c-myc primers in order to amplify endogenous and transgenic c-myc.
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environment, strongly deregulates c-myc and mimics the critical
features promoting human BL. However, we show in the present study
that, unlike human BL that arise from somatically mutated, post-GC B
cells, tumors from c-myc-3′LCR transgenic mice did not express the
BCL-6 protein and showed insigniﬁcant levels of somatic mutation in
VH sequences. Transgenic c-myc had accumulated mutations in key
regulatory sequences located in 5′ and 3′ of P1/P2 promoters
suggesting their role in c-myc deregulation. Comparison of gene
expression proﬁle of BL and anaplastic lymphoma from c-myc-3′LCR
transgenic mice revealed thousands of genes speciﬁcally altered in
each type of tumors showing the genetic complexity generated by c-
myc deregulation. This study deﬁnes more closely the molecular
origin of mouse lymphoma in c-myc-3′LCR transgenic mice and
highlights the necessary inﬂuence of factors operating in addition to c-
myc overexpression. Hypermutation within the ﬁrst exon and 5′
ﬂanking sequences indeed appears as a constant feature for lympho-
magenesis in this mouse model of BL, and reveals an unexpected
uncoupling of the SHM process in the deregulated oncogene, behaving
as an SHM trap, and in the endogenous Ig loci, which remain
essentially unmutated in all cases of lymphoma analysed.
2. Materials and methods
2.1. Generation and characterization of c-myc-′LCR transgenic mice
As shown in Fig. 1, the transgene consisted in a cassette carrying a
mouse c-myc genomic fragment containing c-myc exons and its
natural 5′ untranslated regulatory region encompassing P1 and P2
promoters. The c-myc gene thus falls under the control of the four 3′
IgH enhancers assembled according to their endogenous palindromic
conﬁguration. The cassette was ﬂanked by two copies of the chicken
β-globin HS4 insulator. C-myc–3′LCR transgenic mice showed an
increased c-myc expression in B-cells and an elevated B-cell
proliferation in response to LPS or anti-CD40. Constitutive c-myc
expression led to clonal B-cell neoplasms (B220+IgM+IgD+) with an
overall incidence of 80% by 32 weeks of age; 75% being characterised
as BL and 25% as anaplastic lymphoma [10].2.2. BCL-6 immunohistochemistry of tumors
Lymphomas were stained for BCL-6 using a rabbit polyclonal IgG
antibody (clone N-3, Santa Cruz Biotechnology, Inc, CA).
2.3. Real time polymerase chain reaction
B cells from lymph node tumors of c-myc–3′LCR transgenic mice or
control wild type (wt) mice were puriﬁed using CD43-coupled beads
from Miltenyi Biotec (Bergisch Gladbach, Germany) according to the
manufacturer's recommendations. Total RNA was extracted using tri-
reagent (Ambion, Austin, TX). RNA was reverse-transcribed into cDNA
byaddition of reverse transcriptase to 2 μg total RNA in aﬁnal volumeof
20 μl. QPCRwasperformed induplicate by using TaqManassay reagents
and analysed on an ABI Prism 7000 system (Applied Biosystems Foster
City, CA). Product reference for Msh2: Mn00500563-m1; for Msh6:
Mn00487769-g1; for UNG:Mn00449156-m1; for POLη: Mn00453168-
m1; for REV1: Mn00450983-m1; for AID: Mn01184115-m1; for BCL-6:
Mn00477633-m1; for 18 S RNA (used for normalization of gene
expression levels): Hs99999901-s1.
2.4. Sequence analysis of c-myc gene and expressed VH genes
Genomic DNA extracted from tumors was ampliﬁed by PCR with
the Takara Ex Taq (Lonza, Verviers, Belgique). Locations of PCR primers
are indicated in Fig. 1. Forward wt c-myc primer: 5′-CGGGGGCTCCTA-
GATAACTC-3′; forward transgenic c-myc primer: 5′-AAATC-
GAATTCCCGGTCGAC-3 ′ ; backward c-myc pr imer: 5 ′ -
GACCACCAGATCTG TGCTTA-3′. Concerning VH genes: forward pri-
mers: VHJ558 5′-GCGAAGCTT ARGCCTGGGRCTTCAGTGAAG-3′ and
VHQ52 5′-GCGAAGCTTCTCACAGAGCCTGT CCATCAC-3′; backward
primer: JH4 5′-AGGCTCTGAGATCCCTAGACAG-3′. The PCR products
were cloned into the pCRII-TOPO vector (Invitrogen, Leek, The
Netherlands) and sequenced with an automated laser ﬂuorescent
DNA ABI-PRISM 310 sequencer (Perkin-Elmer, Branchburg, NJ).
Sequence analysis was performed using the MultAlin program
(http://www.bioinfo.genopole-toulouse.prd.fr/multalin/multalin.
html) [11]. Transcription factor binding sites within sequences were
identiﬁed using the Genomatix Suite of sequence analysis tools
(MatInspector, http://www.genomatix.de) [12].
2.5. Microarray analysis
Gene expression proﬁles of c-myc–3′LCR tumors from lymph nodes
were compared with lymph node B cells from wt animals. Experi-
ments were done in triplicate (each sample consisted of RNA from two
BL, two anaplastic lymphomas or two wt B cells, respectively). cDNA
labelling, dual color microarray hybridization and microarray data
analysis were done in “Montpellier Genopole Microarray Facility”
(France) as previously described [10,13].
3. Results
3.1. Analysis of BCL-6 expression in tumors of c-myc–3′LCR transgenic
mice
BCL-6 is a nuclear protein selectively expressed in mature B cells
within normal germinal centers as in their transformed counterparts
[14]. We ﬁrst used real time PCR to analyse BCL-6 RNA expression in
tumors (BL and anaplastic lymphoma) of c-myc–3′LCR transgenic mice
(Fig. 2, upper panel). Lymph node-derived tumors showed markedly
low levels of BCL-6 transcripts in the BL tumors (p=0.005, Mann–
Whitney U-test) (relative expression of 10.0±1.9, mean±SEM of nine
animals) as compared with B-cells from wt lymph nodes (relative
expression of 181.8±28.9, mean±SEM of four animals). BCL-6 RNA
expression was also signiﬁcantly (p=0.01) lower in anaplastic
Fig. 2. Detection of BCL-6 transcripts and protein in tumor from c-myc–3′LCR mice. Upper panel: Analysis by real time PCR of BCL-6 transcript levels in lymph nodes from BL mice,
anaplastic lymphoma mice, andwtmice. BCL-6 levels were normalized to 18 S RNA. Amounts of BCL-6 transcripts were compared to sample with the lowest level of BCL-6 (a BL who
was arbitrary quoted 1). Statistical analysis was made using the Mann–Whitney U-test. Lower panel: Immunostaining with antibodies against the BCL-6 protein reveals no signiﬁcant
binding in BL and an intense staining in lymph node from wt mice.
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controls. Finally BCL-6 transcripts levels were higher (p=0.02) in
anaplastic lymphoma than in BL. To conﬁrm results based on RNA
analysis, we performed parallel immunohistochemical analysis of
BCL-6 protein (Fig. 2, lower panel). In wt lymph node, a speciﬁc
reactivity was detectable that uniformly stained germinal centers.
Consistent with results obtained with real time PCR, no signiﬁcant
BCL-6 staining was found neither in c-myc–3′LCR tumors indepen-
dently of their histotype: BL (Fig. 2, lower panel) nor in anaplastic
lymphoma (data not shown).Table 1
VH gene sequence analysis of c-myc–3′LCR tumors
Tumor number Tumor phenotype VH family JH segment % of homology
1 BL Q52 JH1 100
2 BL J558 JH2 100
3 BL J558 JH3 100
4 Anaplastic lymphoma J558 JH3 100
5 Anaplastic lymphoma Q52 JH4 99.7⁎
At least ﬁve PCR products derived for each tumor were sequenced.
⁎ One mutation was detected on 420 bases.3.2. Analysis of Ig VH gene sequences
In a next set of experiments we analysed the mutation status of VH
rearranged genes in B-cell tumors of c-myc–3′LCR mice. This study
was made possible because of the clonal nature of c-myc–3′LCR-
derived B-cell lymphomas [10]. Results from 5 tumors (three BL and
two anaplastic lymphomas) are summarized in Table 1. All were
essentially unmutated except for a single mutation within one JH
segment. Five different rearrangements associating two different V
families (Q52 and J558) and four J ones (J1, J2, J3 and J4) were
documented.
3.3. The transgenic c-myc gene had accumulated mutations within the
ﬁrst exon and 5′ ﬂanking sequences
To determine the background level of mutations in our sequencing
protocol we ﬁrst sequenced the construct used for generation of c-
myc–3′LCR transgenic mice. Only two mutations were observed in
more than 7000 bp sequenced, thus estimating the background
attributable to PCR error alone at 0.028%. As shown in Fig. 1, speciﬁc
PCR primers were used to distinguish between c-myc originating from
the endogenous or from the transgenic c-myc–3′LCR tumors. No
Fig. 3. Mutational analysis of the ﬁrst exon and 5′ ﬂanking sequences of transgenic c-myc in c-myc–3′LCR tumors. Six BL and ﬁve anaplastic lymphomas were investigated.
Locations of P1 and P2 promoters are indicated. Each small segment represents 25 bp intervals. Bars indicate single base pair substitutions. Triangles indicate deletions. Star
indicates insertion.
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c-myc (data not shown). In contrast numerous mutations were found
in the transgenic c-myc both in BL and anaplastic lymphoma (Fig. 3).
Mutations were located both within the ﬁrst exon and 5′ ﬂanking
sequences, and were predominantly point mutations, although
deletions and insertions were occasionally observed. Transitions
represented 78.2% and 82.1% of mutations in BL and anaplastic
lymphoma, respectively. Among them A↔G and C↔T transition
represented 55% and 45% of mutations, respectively. Transversions
represented 17.8% and 12.5% of mutations in BL and anaplastic
lymphoma, respectively. Deletions represented 2.5% and 5.3% of
mutations in BL and anaplastic lymphoma, respectively. Insertions
represented 1.3% and 0% of mutations in BL and anaplastic lymphoma,
respectively. As shown in Fig. 4, 18% of positions mutated in BL were
also mutated in anaplastic lymphoma (indicated as “m” for mixed in
the ﬁgure) when 42% were found only in BL and 40% in anaplastic
lymphoma. The sequence ﬂanking the P1/P2 promoters were analysed
to locate the presence of potential nuclear factor binding sites [12]. As
shown in Fig. 4, numerousmutationswere located in potential nuclear
factor binding sites such as CREB, SZF1, NFE2/COUP, MYB, IRF3, NKX,HNF1, ZNF1 202, NFAT, PTX1, DEAF/NURD, RREB, RFX1, PAX5, PAX6,
HMGIY and GREF.
3.4. Analysis of transcripts for enzymatic activities implicated in SHM in
c-myc–3′LCR tumors
We, thus, documented that transition mutations are far more
frequent than transversion mutations in c-myc–3′LCR tumors. This
phenomenon is a well known characteristic of mutations induced by
activation-induced deaminase (AID) [6]. Somatic hypermutation
(SHM) introduces nucleotide substitution into immunoglobulin
variable (Ig V) region genes at all four bases. Mutations at C/G
pairs are a direct consequence of C→U deamination catalysed by AID
within WRC motifs. The resulting U/G mispair is recognized by the
UNG uracil-DNA glycosylase. UNG-mediated recognition followed by
replication by error-prone polymerases such as REV1 results in the
generation of both transition and transversion substitutions around
the initially mutated C/G pairs. MSH2/MSH6-mediated recognition of
the U/G mispair triggers a polymerase η (POLη)-dependent patch
repair process which results in mutations at A/T pairs [6]. As shown
Fig. 4. Mutations in BL and anaplastic lymphoma and location of potential transcription factor binding sites. The location of all mutations found in six BL and ﬁve anaplastic
lymphomas are reported. Potential transcription factor binding site are indicated and their most conserved bases are underlined. Letters a, b and m indicate a substitution
found in BL, in anaplastic lymphoma or both, respectively. Triangles indicate a deletion. Stars indicate an insertion. The locations of TATA box, P1 and P2 promoters are
indicated.
Fig. 5. Detection of transcripts for enzymatic activities implicated in somatic
hypermutation in tumor from c-myc–3′LCR mice. Analysis by real time RT-PCR of AID,
MSH2, MSH6, UNG, POLη, and REV1 transcript levels BL (●) and diffuse anaplastic
lymphoma (○) of c-myc–3′LCR mice. Levels were normalized to 18 S RNA. Amounts of
AID, MSH2, MSH6, UNG, POLη, and REV1 transcripts were compared to sample with the
lowest level of AID, MSH2, MSH6, UNG, POLη, and REV1 transcripts, respectively (a BL
who was arbitrary quoted 1).
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were detected in BL and anaplastic lymphoma from c-myc–3′LCR
mice. No signiﬁcant differences were found between BL and diffuse
anaplastic lymphoma (pN0.1, Mann–Whitney U-test).
3.5. Gene expression proﬁle of BL and anaplastic lymphoma from
c-myc–3′LCR mice
The gene expression proﬁle of BL and anaplastic lymphoma was
compared with wt lymph node-derived B cells using an array of
16,643 genes. As previously reported 2125 genes signiﬁcantly differed
between BL as compared with controls and 2000 genes were altered
in diffuse anaplastic lymphomas as compared with controls [10]. In a
new set of analysis, we speciﬁcally focussed our attention on genes
that were only altered in BL or in anaplastic lymphoma. In our study,
856 genes were speciﬁcally altered in BL but not in anaplastic
lymphoma as compared with controls. In turn, 767 other genes were
speciﬁcally altered in anaplastic lymphoma but not in BL as compared
with controls. Genes were classiﬁed into speciﬁc functional categories
using a classiﬁcation system designed by the gene ontology (GO)
consortium (www.geneontology.org): molecular function (MF), bio-
logical process (BP) and cellular component (CP). For BL, 282 genes,
300 genes and 274 genes were found in the BP, MF and CP group,
respectively. For anaplastic lymphoma, 249 genes, 269 genes and 249
genes were found in the BP, MF and CP group, respectively. A similar
GO pattern was thus documented in BL and diffuse anaplastic
lymphoma. Annotated genes were then clustered in meaningful
biological categories and comparison was made between BL and
anaplastic lymphoma. Speciﬁc differences (pb0.05) for genes impli-
cated in MF, BP and CP are reported in Tables 2, 3 and 4, respectively.Taken altogether data showed that BL noticeably exhibited marked
alterations in genes implicated in cell proliferation: base processing,
DNA replication, ribosome assembly and mRNA processing in the BP
group; ATPase, helicase, nuclease and hydrolase activities in the MF
group; nuclear chromosome and spliceosome for the CP group. In
contrast, diffuse anaplastic lymphoma exhibited marked alterations in
genes implicated in cell-to-cell homeostasis: secretory pathway,
response to stimulus, chemotaxis and locomotory behaviour for the
Table 2
Distribution of genes of the molecular function group that were differently affected in
Burkitt-like lymphoma and diffuse anaplastic lymphoma
GO Name P
value
Genes both in
BL and
anaplastic
lymphoma
Genes
only
in BL
Genes only
in
anaplastic
lymphoma
GO:0003674 Molecular function 347 300 269
GO:0003676 Nucleic acid binding 0.050 59 73 48
GO:0003723 RNA binding 0.016 18 24 9
GO:0008135 Translation factor
activity, nucleic acid
binding
0.025 3 10 2
GO:0005515 Protein binding 0.024 138 101 115
GO:0005102 Receptor binding 0.001 10 3 16
GO:0001664 G-protein-coupled
receptor binding
0.025 0 0 5
GO:0042379 Chemokine receptor
binding
0.025 0 0 5
GO:0008009 Chemokine activity 0.025 0 0 5
GO:0005125 Cytokine activity 0.001 4 0 10
GO:0004386 Helicase activity 0.014 4 9 1
GO:0019829 Cation-transporting
ATPase activity
0.048 1 4 0
GO:0046961 Hydrogen ion
transporting ATPase
activity, rotational
mechanism
0.048 1 4 0
GO:0016887 ATPase activity 0.033 5 15 5
GO:0042623 ATPase activity, coupled 0.015 5 15 4
GO:0016788 Hydrolase activity,
acting on ester bonds
0.018 19 19 6
GO:0004518 Nuclease activity 0.031 4 5 0
GO:0003899 DNA-directed RNA
polymerase activity
0.045 0 4 0
GO:0045182 Translation regulator
activity
0.025 3 10 2
GO:0046933 Hydrogen ion
transporting ATP
synthase activity,
rotational mechanism
0.048 1 4 0
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MF group; genes implicated in cell-to-cell contact for the CP group.
4. Discussion
Human BL express surface IgM and their expression of BCL-6
suggests a GC origin. Sequence analysis of the Ig VH genes conﬁrms that
BL have arisen from GC B cells, with evidence of somatic hypermuta-
tion. Thehallmark of humanBL is the overexpression of c-myc resulting
from t(8:14) and c-myc deregulation seems to be the key step in
lymphomagenesis [2]. Consistent with this critical role of c-myc, mice
model carrying insertion of this oncogene into the IgH locus develop B
cell and plasma cell neoplasms [15,16]. The c-myc gene deregulation
can be attributed to its juxtaposition to the IgH locus 5′ (i.e., Eμ) and 3′
(i.e., 3′LCR) transcriptional regulatoryelements.During thepastdecade
Eμwasused to deregulate c-myc in the aimofmimickinghumanBL, but
such transgenic mice in fact developed malignancies with a pro-B
phenotype rather than the mature phenotype observed in BL [17].
Recently the 3′LCRwas used to deregulate c-myc. The four 3′ enhancers
acting as an LCR downstream of the IgH locus and able to act
synergistically at long distances [18] are important for both B cell
receptor (BCR) expression on resting B cells and germline transcription
of constant gene prior to class switch recombination (CSR) [19].
Transgenic mice bearing a c-myc–3′LCR construct developed BL and
anaplastic lymphoma at a medium age of 12 weeks [10]. Interestingly
the model of c-myc–3′LCR transgenic mice induced two kinds of B cell
neoplasia comparable to those in the model mimicking the t(8:14)
translocation of Park et al. [15,16], with amajor difference in the kinetic
of apparition. The most prevalent neoplasm in our model had featurestypical of human BL: clonal tumors of medium-sized mature B cells
with basophilic cytoplasms overexpressed c-myc and showed a typical
“starry sky” histological morphology [10].
HumanBLareconsideredasarising fromsomaticallymutated, post-
GC B cells; their BCL-6 expression reinforcing their post-GC status [7].
Moreover aberrant hypermutation is suggested as a major contributor
to lymphomagenesis. Thus, AID is required for GC-derived lymphoma-
genesis [20] and AID promotes B cell lymphomagenesis in Eμ–c-myc
transgenic mice [21]. In themodel mimicking the t(8:14) translocation
of Park et al.. [15, 16], BL expressed BCL-6 protein but did not reveal
signiﬁcant levels of somatic mutation of Ig VH sequences suggesting
that BL arise from naïve B cells. Of interest, Kovalchuk et al. [22] have
reported that mice bearing a myc gene controlled by a reconstructed
Igλ locus encompassing all the elements required for establishment of
locus control in vitro also exhibited BL tumors with unmutated V
regions. Results of the present study using c-myc–3′LCR transgenic
mice conﬁrm the absence of V mutations but by contrast reveal that
cells went through the AID expressing stage and carry highly mutated
c-myc sequences. In our model, BL cells did not express BCL-6 protein
andexpressedvery lowlevelsof BCL-6 transcripts as comparedwithGC
B cells. With regard to antigen-drivenmaturation BL cells from c-myc–
3′LCR transgenic mice did not reveal signiﬁcant levels of somatic
mutation of Ig VH sequences and could, thus, be considered as naïve.
Taken altogether these results suggest that in mice the constitutive
expression of c-myc is able to promote proliferation and selection
within GC or GC-like structure in the absence of antigen-driven
selection. Studies with transgenic animals, bearing the green ﬂuor-
escent protein or c-myc as reporter genes, have reported that the 3′LCR
is active since the pre-B cell stage and throughout B-cell development
[23, 24]. Transgenic c-mycmutation may, thus, occur at any stage of B
cell maturationwhere the SHMmachinery is active. However, the high
level of somatic mutation in the c-myc sequence (close to 2%) and the
pattern of mutation not only targeting WRC motifs but also largely
affecting sequences around, strongly suggest the involvement of not
only AID for ﬁrst-phase mutations of G/C pairs but also the complete
SHM machinery for patch repair by Exo1, MSH2/MSH6 and POLη [6].
This pattern thus points to GC or to equivalent structures for the
selection of cells “improving” transgenic c-myc proliferative effect
instead of improving antigen recognition.
Chromosomal translocation involving c-myc has long been
suggested as unable by itself to support the development of
lymphoma unless associated to additional genetic alterations [2,25].
In c-myc–3′LCR mice, besides the deregulation of a variety of genes
revealed by transcriptome analysis, remodelling of the c-myc
promoter region by SHM appears as a constant feature. Interestingly,
mutations in non-Ig genes including not only c-myc but also
oncogenes such as PAX5, BCL-6, PIM1, P53 and Rb have been reported
in human BL [21,25]. Sequence analysis of c-myc has, thus, shown
point mutations concentrated around the conserved so-called Myc
box 1 decreasing the proteasome-mediated c-myc turnover and
thereby increasing c-myc half life [25]. Other point mutations were
reported within the ﬁrst c-myc exon and 5′ ﬂanking sequences
[26,27]. It was suggested that these mutations lead to constitutive
oncogene expression through inactivation of negative regulatory
element binding sites [26,27]. A similar situation is re-created in c-
myc–3′LCR transgenic mice. Sequence analysis of tumors in these
animals revealed the presence of somatic mutations both 5′ and 3′ of
transgenic P1/P2 c-myc promoters. While some mutations were
found within binding sites for nuclear factor implicated in chromatin
opening such as HMGIY and may positively affect their efﬁciency [28],
many of these mutations were found in negative transcription factor
binding sites such as DEAF-1 [29], PAX5 [30], NKX [31], NR2F/COUP
[32], RFX1 [33], HNF1 [34], PTX1 [35], RREB [36], ZNF 202 [37], CREB
[38], GREF [39], IRF [40], MYB [41] and NFAT [42]. A number of
studies identiﬁed these factors as negative regulators of c-myc
expression. Nuclear factor RFX1 has been reported to cause down-
Table 3
Distribution of genes of the biological process group that were differently affected in
Burkitt-like lymphoma and diffuse anaplastic lymphoma
GO Name P
value
Genes both
in BL and
anaplastic
lymphoma
Genes
only
in BL
Genes only
in
anaplastic
lymphoma
GO:0008150 Biological process 332 282 249
GO:0001505 Regulation of
neurotransmitter levels
0.037 3 0 4
GO:0000278 Mitotic cell cycle 0.032 9 8 1
GO:0022618 Protein-RNA complex
assembly
0.027 1 5 0
GO:0006413 Translational initiation 0.048 1 4 0
GO:0048193 Golgi vesicle transport 0.045 0 0 4
GO:0006888 Endoplasmic reticulum to
Golgi vesicle-mediated
transport
0.045 0 0 4
GO:0006913 Nucleocytoplasmic
transport
0.030 3 5 0
GO:0032940 Secretion by cell 0.011 9 1 8
GO:0045045 Secretory pathway 0.020 8 1 7
GO:0000226 Microtubule cytoskeleton
organization and
biogenesis
0.048 1 4 0
GO:0042254 Ribosome biogenesis and
assembly
0.001 2 12 0
GO:0006364 rRNA processing 0.009 2 7 0
GO:0022613 Ribonucleoprotein
complex biogenesis and
assembly
0.001 3 15 0
GO:0006066 Alcohol metabolic process 0.010 11 1 8
GO:0006576 Biogenic amine metabolic
process
0.039 2 0 4
GO:0051188 Cofactor biosynthetic
process
0.037 6 5 0
GO:0009108 Coenzyme biosynthetic
process
0.037 6 5 0
GO:0006754 ATP biosynthetic process 0.048 1 4 0
GO:0015986 ATP synthesis coupled
proton transport
0.048 1 4 0
GO:0009165 Nucleotide biosynthetic
process
0.017 7 9 1
GO:0009142 Nucleoside triphosphate
biosynthetic process
0.028 2 5 0
GO:0009145 Purine nucleoside
triphosphate biosynthetic
process
0.028 2 5 0
GO:0009206 Purine ribonucleoside
triphosphate biosynthetic
process
0.028 2 5 0
GO:0009201 Ribonucleoside
triphosphate biosynthetic
process
0.028 2 5 0
GO:0006164 Purine nucleotide
biosynthetic process
0.046 5 7 1
GO:0009152 Purine ribonucleotide
biosynthetic process
0.032 4 5 0
GO:0009260 Ribonucleotide
biosynthetic process
0.018 4 6 0
GO:0006643 Membrane lipid metabolic
process
0.044 4 1 6
GO:0006665 Sphingolipid metabolic
process
0.039 2 0 4
GO:0006486 Protein amino acid
glycosylation
0.020 3 0 5
GO:0006412 Translation 0.040 15 26 12
GO:0046034 ATP metabolic process 0.048 1 4 0
GO:0006752 Group transfer coenzyme
metabolic process
0.028 2 5 0
GO:0006753 Nucleoside phosphate
metabolic process
0.048 1 4 0
GO:0006139 Nucleobase, nucleoside,
nucleotide and nucleic
acid metabolic process
0.020 78 88 56
GO:0006260 DNA replication 0.022 12 13 3
GO:0006261 DNA-dependent DNA
replication
0.028 2 5 0
GO:0006396 RNA processing 0.001 9 16 2
Table 3 (continued)
GO Name P
value
Genes both
in BL and
anaplastic
lymphoma
Genes
only
in BL
Genes only
in
anaplastic
lymphoma
GO:0008380 RNA splicing 0.016 2 6 0
GO:0006397 mRNA processing 0.046 5 7 1
GO:0016071 mRNA metabolic process 0.046 5 7 1
GO:0016072 rRNA metabolic process 0.009 2 7 0
GO:0009117 Nucleotide metabolic
process
0.033 9 10 2
GO:0009141 Nucleoside triphosphate
metabolic process
0.016 2 6 0
GO:0009144 Purine nucleoside
triphosphate metabolic
process
0.016 2 6 0
GO:0009205 Purine ribonucleoside
triphosphate metabolic
process
0.028 2 5 0
GO:0009199 Ribonucleoside
triphosphate metabolic
process
0.028 2 5 0
GO:0006163 Purine nucleotide
metabolic process
0.026 5 8 1
GO:0009150 Purine ribonucleotide
metabolic process
0.032 4 5 0
GO:0009259 Ribonucleotide metabolic
process
0.018 4 6 0
GO:0006119 Oxidative phosphorylation 0.015 1 6 0
GO:0032502 Developmental process 0.032 68 45 58
GO:0007423 Sensory organ
development
0.025 0 0 5
GO:0051236 Establishment of RNA
localization
0.025 0 5 0
GO:0050658 RNA transport 0.025 0 5 0
GO:0051028 mRNA transport 0.025 0 5 0
GO:0046903 secretion 0.032 10 2 8
GO:0015985 Energy coupled proton
transport, down
electrochemical gradient
0.048 1 4 0
GO:0015931 Nucleobase, nucleoside,
nucleotide and nucleic
acid transport
0.015 1 6 0
GO:0050657 Nucleic acid transport 0.025 0 5 0
GO:0002250 Adaptative immune
response
0.036 11 8 1
GO:0002460 Adaptative immune
response based on somatic
recombination of immune
receptors
0.036 11 8 1
GO:0006403 RNA localization 0.025 0 5 0
GO:0043413 Biopolymer glycosylation 0.019 4 0 5
GO:0032501 Multicellular organismal
process
0.037 56 43 56
GO:0050877 Neurological process 0.025 4 1 7
GO:0050896 Response to stimulus 0.002 62 32 53
GO:0007610 Behaviour 0.001 6 1 14
GO:0030534 Adult behaviour 0.042 1 0 4
GO:0008344 Adult locomotory
behaviour
0.042 1 0 4
GO:0007626 Locomotory behaviour 0.001 5 1 13
GO:0042330 Taxis 0.002 4 0 9
GO:0006935 Chemotaxis 0.002 4 0 9
GO:0006952 Defense response 0.012 13 7 18
GO:0042221 Response to chemical
stimulus
0.002 15 3 15
GO:0009605 Response to external
stimulus
0.008 11 7 19
424 C. Vincent et al. / Biochimica et Biophysica Acta 1793 (2009) 418–426regulation of c-myc expression in undifferentiated HL-60 cells [33].
Cellular depletion of the CREB-binding protein stimulated c-myc
expression and promoted entry of cell in S phase [38]. Deletion of a
glucocorticoid response element (GRE) located 5′ of the myc
promoter increased its basal activity in transient transfection assay
[39]. Interferon regulatory factor (IRF)-1 has been reported to inhibit
cell proliferation and oncogenic transformation mediated by c-myc
Table 4
Distribution of genes of the cellular component group that were differently affected in
Burkitt-like lymphoma and diffuse anaplastic lymphoma
GO Name P
value
Genes both in
BL and
anaplastic
lymphoma
Genes
only in BL
lymphoma
Genes only
in anaplastic
lymphoma
GO:0005575 Cellular
component
340 274 249
GO:0019717 Synaptosome 0.045 0 0 4
GO:0043231 Intracellular
membrane-bound
organelle
0.030 145 142 106
GO:0005634 Nucleus 0.003 66 84 49
GO:0044428 Nuclear part 0.006 17 35 15
GO:0000228 Nuclear
chromosome
0.039 3 7 1
GO:0044454 Nuclear
chromosome part
0.039 3 7 1
GO:0005681 Spliceosome 0.027 2 5 0
GO:0044446 Intracellular
organelle part
0.012 62 68 40
GO:0030529 Ribonucleoprotein
complex
0.001 13 22 3
GO:0016469 Proton-
transporting two-
sector ATPase
complex
0.047 1 4 0
GO:0005576 Extracellular
region
0.001 58 35 61
GO:0044421 Extracellular
region part
0.002 57 34 56
GO:0005615 Extracellular
space
0.002 56 32 55
GO:0032991 Macromolecule
complex
0.001 56 69 32
GO:0043234 Protein complex 0.038 47 52 31
GO:0043226 Organelle 0.021 162 159 120
GO:0043227 Membrane-bound
organelle
0.030 145 142 106
GO:0044422 Organelle part 0.017 62 68 41
425C. Vincent et al. / Biochimica et Biophysica Acta 1793 (2009) 418–426[40]. Altogether and especially when they are combined, the
alterations in the 5′ portion of transgenic oncogene observed in c-
myc–3′LCR mice and targeting negative regulatory elements, likely
play a key role in lymphoma initiation by switching cells from low
level constitutive c-myc expression to high level constitutive
expression. Strengthening this hypothesis, premalignant B-cells
from c-myc–3′LCR mice showed 3-fold higher levels of c-myc
transcripts as compared to wt animals while a 15-fold increase was
found in B cells of lymphoma mice [10]. While the cellular pathway
that may lead a cell to select c-mycmutations instead of selecting BCR
mutations remains to be understood, the pattern and the density of
these mutations clearly provide a GC or GC-like signature, involving
not only AID for ﬁrst-phase mutations and its usual partners in GC for
second-phase mutations (MSH2, MSH6, UNG, POLη and REV1). The
predominance of point mutations with transitions occurring twice
more frequently than transversions was also similar to SHM found on
Ig genes in normal GC [43]. While AID is absolutely required for SHM
in B cells, its expression is not sufﬁcient for SHM. For example, weak
AID expression is detectable in immature B cells that do not undergo
SHM [44]. Besides high-levels AID expression and the presence of co-
factors, target genes need to be accessible to the SHMmachinery, and
the association of the oncogene with 3′ IgH LCR likely plays a key role
for recruiting AID at a stage where the SHM machinery is fully
efﬁcient, such as in GC. Several studies have demonstrated the pivotal
role of Ig-enhancers for the targeting of the Ig-mutator system [45].
The mutation rate of a targeted gene is also inﬂuenced by its
transcription level [46].
C-myc–3′LCR transgenic mice developed lymphomas within few
weeks [10]. BL proliferations occurred in 75% of cases while theremaining 25% were characterized as diffuse anaplastic lymphomas.
These two types of lymphoma appeared with different latency:
12 weeks for BL and 20 weeks for anaplastic lymphoma. Results of
the present study indicate that both types of tumors have an
identical mutational status. They do not express BCL-6 in the case of
BL or only at low level for anaplastic lymphoma. Analysis of gene
expression proﬁles showed that anaplastic lymphoma exhibited
marked alterations in genes implicated in cell-to-cell homeostasis (a
characteristic of cell maturity). In turn, BL exhibited marked
alterations in genes implicated in cell proliferation explaining their
earlier onset. Despite these differences, these tumors apparently
arise through a very similar and unique pathway: sequence analysis
of their Ig VH sequences would classify them as naïve B cells, while
by contrast they appear to have corrupted the SHM machinery in
order to replace afﬁnity maturation with “oncogene maturation”
during GC phase.
Transgenic mouse models that reproduce the t(8:14) which is the
hallmark of human BL are of importance in elucidating the
mechanism by which deregulated c-myc leads to human BL. Our
model of c-myc–3′LCR transgenic mice is one of these models among
those already developed by Park et al. [15,16] and Wang and Boxer
[47]. Transgenic mouse models are also instrumental in dissecting
the role of genetic and epigenetic changes in human BL. BL
development involves multiple genetic and epigenetic changes that
drive cell cycle progression and prevent cell death by apoptosis [25].
Our transgenic model reveals accumulated mutations within the ﬁrst
exon and 5′ ﬂanking sequences of transgenic c-myc. Such phenom-
enon has been previously reported in human BL [26]. Differences in
patterns of c-myc transcription observed in human BL may, thus,
reﬂect differences of mutations in the translocated c-myc. Analysis of
mutations within the ﬁrst exon and 5′ ﬂanking sequences of c-myc in
human BL might be of interest in classifying BL tumors as low or high
aggressive and/or low or high responsive with regard to chemother-
apeutic treatments. The rapid occurrence of lymphoma in c-myc–3′
LCR transgenic mice makes it an interesting tool for therapeutics
testing. However whether our transgenic mice seem of great interest
in elucidating some important events leading to human BL such as
mutations, we must admit that they are not a silver bullet which fully
mimics the occurrence of human BL. Thus, c-myc–3′LCR tumors had
no evident alteration of the apoptotic pathway [10], a phenomenon
frequently found in human BL [25].
In conclusion BL and diffuse anaplastic lymphoma in c-myc–3′
LCR transgenic mice arise from a non-mutated “antigenically naïve”
cell, which skips the process of antigen-driven selection for
replacing it by oncogene-driven selection. While 3′ IgH transcrip-
tional enhancers in c-myc–3′LCR transgenic mice may act in cis to
stimulate c-myc expression, a constant second hit, is thus provided
by accumulated mutations within the ﬁrst exon and 5′ ﬂanking
sequences of c-myc, which may inactivate regulatory elements and
switch the cell from a pre-malignant stage with slight c-myc
overexpression to a malignant stage driven by high-level constitu-
tive oncogene expression.
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